Dr. Edwin P. Alyea

Dr. Edwin P. Alyea har specialiseret sig i behandling af blodkræftpatienter, der overvejer stamcelle- eller knoglemarvstransplantationer. I løbet af de sidste 20 år er der sket betydelige fremskridt inden for transplantation, hvilket har resulteret i bedre resultater. Disse fremskridt omfatter evnen til at bruge lavere kemoterapidoser for at mindske toksiciteten hos patienter, samt metoder til at reducere sandsynligheden for tilbagefald. Jeg er interesseret i at bruge nye lægemidler og teknikker til at forbedre resultaterne efter stamcelletransplantation for maligne blodsygdomme. Det er afgørende at samarbejde med patienterne for at definere deres behandlingsmål og den bedste fremgangsmåde. I mange år efter deres transplantation har jeg elsket at arbejde med patienter og deres familier.

Board certificering

American Board of Internal Med, Medical Oncology

Fællesskab

Medicinsk onkologi, Dana-Farber Cancer Institute (Massachusetts), 1992-1995

Residency

Intern medicin, Brigham and Women's Hospital (Massachusetts), 1989-1992

Uddannelse

MD, Duke University, 1989

• Voksen knoglemarv og stamcelletransplantation
• Autolog Transplantation
• Allogen transplantation
• Syngen transplantation

• Hourigan, Christopher S., Laura W. Dillon, Gege Gui, Brent R. Logan, Mingwei Fei, Jack Ghannam, Yuesheng Li, et al. “Impact of Conditioning Intensity of Allogeneic Transplantation for Akut myeloid leukæmi With Genomic Evidence of Residual Disease.” J Clin Oncol 38, nr. 12 (20. april 2020): 1273–83. https://doi.org/10.1200/JCO.19.03011.
• Soiffer, Robert J., Haesook T. Kim, Joseph McGuirk, Mitchell E. Horwitz, Laura Johnston, Mrinal M. Patnaik, Witold Rybka, et al. “Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.” J Clin Oncol 35, nr. 36 (20. december 2017): 4003-11. https://doi.org/10.1200/JCO.2017.75.8177.
• Liu, Hien Duong, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani, Taiga Nishihori, Baldeep Wirk, Amer Beitinjaneh, et al. “Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.” Biol Blodmarvstransplantation 23, nr. 5 (maj 2017): 767–75. https://doi.org/10.1016/j.bbmt.2017.01.078.
• Scott, Bart L., Marcelo C. Pasquini, Brent R. Logan, Juan Wu, Steven M. Devine, David L. Porter, Richard T. Maziarz, et al. “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastisk Syndromes.” J Clin Oncol 35, nr. 11 (10. april 2017): 1154–61. https://doi.org/10.1200/JCO.2016.70.7091.
• Shaffer, Brian C., Kwang Woo Ahn, Zhen-Huan Hu, Taiga Nishihori, Adriana K. Malone, David Valcárcel, Michael R. Grunwald, et al. “Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.” J Clin Oncol 34, nr. 16 (1. juni 2016): 1864–71. https://doi.org/10.1200/JCO.2015.65.0515.
• Devine, Steven M., Kouros Owzar, William Blum, Flora Mulkey, Richard M. Stone, Jack W. Hsu, Richard E. Champlin, et al. “Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.” J Clin Oncol 33, nr. 35 (10. december 2015): 4167-75. https://doi.org/10.1200/JCO.2015.62.7273.
• Jacobson, Caron A., Lixian Sun, Haesook T. Kim, Sean M. McDonough, Carol G. Reynolds, Michael Schowalter, John Koreth, et al. “Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.” Biol Blodmarvstransplantation 20, nr. 5 (maj 2014): 668–75. https://doi.org/10.1016/j.bbmt.2014.01.021.
• Cutler, Corey, Haesook T. Kim, Bhavjot Bindra, Stefanie Sarantopoulos, Vincent T. Ho, Yi-Bin Chen, Jacalyn Rosenblatt, et al. “Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.” Blood 122, nr. 8 (22. august 2013): 1510-17. https://doi.org/10.1182/blood-2013-04-495895.
• Porcheray, Fabrice, David B. Miklos, Blair H. Floyd, Stefanie Sarantopoulos, Roberto Bellucci, Robert J. Soiffer, Joseph H. Antin, Edwin P. Alyea, Jerome Ritz, and Emmanuel Zorn. “Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation.” Transplantation 92, nr. 3 (15. august 2011): 359-65. https://doi.org/10.1097/TP.0b013e3182244cc3.